Mon Aug 31 14:43:34 SGT 2015  
SINGAPORE
SEXUALHEALTH™
    Genital Warts
SINGAPORE SEXUALHEALTH™
HIV PEP (post-exposure prophylaxis): Stop HIV infection within 3 days after unprotected sex.
HIV test: 20 minute rapid test to accurately detect HIV infection 28 days after unprotected sex.
STD testing: Full & comprehensive sexually transmitted disease testing.

Genital Warts | SINGAPORE SEXUALHEALTH™

Summary

Genital Warts | SINGAPORE SEXUALHEALTH™ @singaporesexualhealth_com: Genital warts, Singapore. Private & confidential service.

Advertisement: Come to sunny Singapore to have your testing and treatment. Singapore Ministry of Health registered general practice (GP) clinic:
SHIM CLINIC
SINGAPORE SEXUALHEALTH™
168 Bedok South Avenue 3 #01-473
Singapore 460168
Tel: (+65) 6446 7446
Fax: (+65) 6449 7446
24hr Answering Tel: (+65) 6333 5550
Web: www.shimclinic.com
Opening Hours
Monday to Friday: 9 am to 3 pm, 7 pm to 11 pm
Saturday & Sunday: 7 pm to 11 pm
Public Holidays: Closed
Last registration: one hour before closing time.
Walk-in clinic. Appointments not required.
Bring NRIC, Work Pass or Passport for registration.

Description

Table of Contents

Genital warts: penile warts / vaginal warts / anal warts / anogenital warts / venereal warts / condyloma / condylomata acuminata / "cauliflower" sex disease.

References

Warts - on male sex organ Genital warts appear within 3 months after sexual contact with an infected person.

Genital warts:

  • are usually soft, pink cauliflower-like growths or flesh-coloured bumps on the sex organs
  • may also be hard and smooth
  • occur alone or in groups
  • tend to recur after treatment
  • increase the risk of cervical cancer in women.


Warts - on female sex organ An infected woman may infect her newborn during childbirth.

A person with genital warts can infect others through sexual contact.



Genital warts treatment / HPV treatment

HPV / human papillomavirus.

  • 120 known human papillomavirus (HPV)
  • 51 HPV types, and 3 subtypes are genital HPV as they infect the genital mucosa.
  • 31 genital HPV types are low risk
  • 6 genital HPV types are intermediate risk
  • 17 genital HPV types are high risk
They cause Genital HPV types, cancer risk, vaccine and test coverage
Type
Species
Risk
Cervarix
Gardasil
Gardasil-9
DigeneHR
DigenePS
CobasHPV
Digene
HybriBio
PapilloCheck
InnoLiPA
LinearArray
61 3 L ----------+-
72 3 L ----------+-
81 3 L -------+--+-
83 3 L ----------+-
84 3 L ----------+-
62 3 L ----------+-
CP6108 3 L ----------+-
71 15 L ---------++-
26 5 H ---------++-
51 5 H ---+-++++++-
69 5 H ---------++-
82 5 H --------+++-
IS39 5 H ----------+-
18 7 H +++++++++++-
39 7 H ---+-++++++-
45 7 H --+++++++++-
59 7 H ---+-++++++-
68 7 H ---+-++++++-
70 7 H --------+++-
53 6 H -------++++-
56 6 H ---+-++++++-
66 6 H -----+-++++-
54 13 L ---------++-
42 1 L ------+++-+-
40 8 L --------+++-
43 8 L ------++++--
6 10 L -++---+++++-
11 10 L -++---+++++-
44 10 L ------++++--
74 10 L ---------+--
16 9 H +++++++++++-
31 9 H --++-++++++-
33 9 H --++-++++++-
35 9 H ---+-++++++-
52 9 H --++-++++++-
58 9 H --++-++++++-
67 9 H ----------+-
73 11 H --------+++-

Legend: 71 (CP 8061), 73/MM9, 81 (CP 8304), 82 (MM4), 82 (IS 39), 83 (MM7), 84 (MM8), 89 (CP 6108)

References

Cervical cancer HPV vaccine (previously known as cervical cancer vaccine) types:
  • Gardasil® [HPV (Human Papillomavirus) Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant]
  • Cervarix® [HPV (Human Papillomavirus) Bivalent (Types 16 and 18) Vaccine, Recombinant]
  • V503 [HPV (Human Papillomavirus) Nonavalent (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) Vaccine, Recombinant]
References Gardasil® [HPV (Human Papillomavirus) Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] References Cervarix® [HPV (Human Papillomavirus) Bivalent (Types 16 and 18) Vaccine, Recombinant] References V503 [HPV (Human Papillomavirus) Nonavalent (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) Vaccine, Recombinant] - to be released in 2013 STD vaccine / hepatitis vaccine shot/jab/injection to prevent some STDs

Vaccine Against Disease Age D
o
s
e
s
Dose schedule Price
per
dose
(SG$)
Havrix™ 1440 Adult Hepatitis A virus Hepatitis A ≥19y 2 m 0 & 6-12 $90/=
Twinrix® Hepatitis A virus
Hepatitis B virus
Hepatitis A
Hepatitis B
1-15y 2 m 0, 6-12 $135/=
≥16y 3 m 0, 1, 6
4 d 0, 7, 21 & m 12
Inactivated / Fractional / Protein / Subunit / Recombinant
Engerix™-B 20 μg Hepatitis B virus Hepatitis B 11-15y 2 m 0, & 6 $50/=
≥20y 3 m 0, 1, & 6
4 m 0, 1, 2, & 12 or
d 0, 7, 21 & m 12
Gardasil® HPV
types 6, 11, 16, & 18
Genital warts
Cervical cancer
9-26y 3 m 0, 2, & 6 or
m 0, 1, & 4
$195/=
Cervarix® HPV
types 16, & 18
(31, 33, & 45)
10-25y 3 m 0, 1, & 6
m 0, 1, & 5
m 0, 2½, 12
$195/=
V503 HPV
types 6, 11, 16, 18,
31, 33, 45,
52, & 58
3 m 0, 2, & 6 or
m 0, 1, & 4
$???/=

HPV test for men/women.

  • Digene® High-Risk HPV DNA Test
  • Digene® HPV DNA Test
  • Digene® HPV Genotyping PS Test
  • Hybribio®
    • HPV GenoArray Test Kit
    • Detects 15 high-risk HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, and 68. And 6 low-risk HPV types: 6, 11, 42, 43, 44, CP8304
    • Able to differentiate which types are positive.
    • May be available in Singapore soon.
  • Cobas® HPV Test
    • Cobas® HPV Test
    • Detects 14 high-risk HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68
    • The test specifically identifies (types) HPV 16 and HPV 18, while concurrently detecting the rest of the high risk types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68)
    • Cost is SG$200/=
  • LINEAR ARRAY® HPV Genotyping Test
    • LINEAR ARRAY® HPV Genotyping Test
    • Identifies 37 high-risk HPV genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73 (MM9), 82 (MM4) low-risk HPV genotypes 6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 67, 69, 70, 71, 72, 81, 83 (MM7), 84 (MM8), IS39, and CP6108
  • INNO-LiPA HPV Genotyping Extra
    • INNO-LiPA HPV Genotyping Extra
    • Identifies 15 high-risk HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82) 3 probable high-risk HPV genotypes (26, 53, 66) 7 low-risk HPV genotypes (6, 11, 40, 43, 44, 54, 70) and some additional types (69, 71, 74).
  • PapilloCheck®
    • PapilloCheck®
    • Identifies 24 hiv-risk HPV types 16 18 31 33 35 39 45 51 52 53 56 58 59 66 68 70 73 82 and low-risk HPV types 6 11 40 42 43 44

Sexual risk (of HIV/STD/pregnancy), and what you can do before and after exposure.

Timeline HIV STD Pregnancy
Before exposure
Abstain from sex, Be faithful, or Condom use
Circumcision (males only)
Contraception (females only)
HIV PrEP (pre-exposure prophylaxis) STD vaccine:
- Hepatitis vaccine
- HPV vaccine
STD / HIV exposure
Unsafe sex / unprotected sex:
No condom / Condom broke / Condom slip
0-72 hours HIV prevention
HIV PEP (post-exposure prophylaxis) treatment
- Stop HIV infection after exposure.
STD testing.
If STD symptoms appear, then do STD treatment.
- Males: Do not urinate for at least 4 hours before arriving.
- Females: testing is more accurate when you are not menstruating.
Emergency contraception (females only)
2 weeks HIV DNA PCR test
1 month 20 minute rapid HIV test - SD Bioline HIV Ag/Ab Combo:
- Fingerprick blood sampling.
3 months 20 minute rapid HIV test - OraQuick®:
- Oral saliva or
- Fingerprick blood sampling.
Full & comprehensive STD testing
- Males: Do not urinate for at least 4 hours before arriving.
- Females: testing is more accurate when you are not menstruating.

References


Latest News

Role of dual specificity tyrosine-phosphorylation-regulated kinase 1B (Dyrk1B) in S-phase entry of HPV E7 expressing cells from quiescence.
Sat, 29 Aug 2015 22:08:03 +0100 | Oncotarget
Authors: Zhou N, Yuan S, Wang R, Zhang W, Chen JJ

Human Papillomavirus Knowledge and Attitude among Homeless Women of New York City Shelters
Sat, 29 Aug 2015 00:00:00 +0100 | Womens Health Issues
Human papillomavirus (HPV) has not been studied among homeless women in the United States. We assessed knowledge and attitudes regarding HPV infection and the HPV vaccine among homeless women. (Source: Womens Health Issues)

Human papillomavirus capsids preferentially bind and infect tumor cells
Fri, 28 Aug 2015 00:00:00 +0100 | International Journal of Cancer
This article is protected by copyright. All rights reserved. (Source: International Journal of Cancer)

No role for human papillomavirus infection in oral cancers in a region in Southern India
Fri, 28 Aug 2015 00:00:00 +0100 | International Journal of Cancer
This article is protected by copyright. All rights reserved. © 2014 Wiley Periodicals, Inc. (Source: International Journal of Cancer)

Returning Relevance to the Women’s Health Visit
Fri, 28 Aug 2015 00:00:00 +0100 | The Journal for Nurse Practitioners
In the 1940s, when the Pap smear was first introduced, cervical cancer was the number one killer of women. Over the years, the annual Pap test became the cornerstone for women’s health care. The campaign became a model for successful cancer prevention, and the result was a dramatic decrease in mortality from cervical cancer in the United States. The guidelines for cervical cancer screening have been revised several times as a result of improved understanding of the role of human papillomavirus in the development of cervical changes that lead to cancer and the unintended consequences of aggressive management of early cervical dysplasia that would likely resolve without intervention, particularly in late adolescent and young adult women. (Source: The Journal for Nurse Practitioners)

Long non-coding RNA MALAT1 modulates radiosensitivity of HR-HPV+ cervical cancer via sponging miR-145
Thu, 27 Aug 2015 00:00:00 +0100 | Tumor Biology
This study explored the role of MALAT1 in radiosensitivity of high-risk human papillomavirus (HR-HPV)-positive cervical cancer and whether there is a ceRNA mechanism which participated in its regulation over radiosensitivity. Based on tissue samples from 50 cervical cancer cases and 25 healthy controls, we found MALAT1 expression was significantly higher in radioresistant than in radiosensitive cancer cases. In addition, MALAT1 and miR-145 expression inversely changed in response to irradiation in HR-HPV+ cervical cancer cells. By using clonogenic assay and flow cytometry analysis of cell cycle distribution and apoptosis, we found CaSki and Hela cells with knockdown of MALAT1 had significantly lower colony formation, higher ratio of G2/M phase block and higher ratio of cell apoptosis. By p...

PATHOS: a phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV) positive oropharyngeal cancer
Thu, 27 Aug 2015 00:00:00 +0100 | BMC Cancer
This study is registered with ClinicalTrials.gov identifier NCT02215265. (Source: BMC Cancer)

Geospatial patterns of human papillomavirus vaccine uptake in Minnesota
Thu, 27 Aug 2015 00:00:00 +0100 | BMJ Open
Conclusions

Single photon emission computed tomography findings after human papillomavirus (HPV) vaccination in Japan
Wed, 26 Aug 2015 22:27:50 +0100 | Autonomic Neuroscience: Basic and Clinical
Almost of previous investigations for adverse clinical symptoms after human papilloma virus (HPV) vaccination described that the symptoms appeared to be complex regional pain syndrome or psychogenic disorders. However we have a chance for investigating over 100 patients with widespread pain, general fatigue, autonomic dysfunction, memory impairment, hyper photosensitivity, impairment of locomotor system, et al. after HPV vaccination. Based on these clinical symptoms, we postulated HPV vaccination associated with neuro-immunopathic syndrome (HANS). (Source: Autonomic Neuroscience: Basic and Clinical)

Subacute autonomic, endocrine, and cognitive disorders in Japanese girls at puberty after human papillomavirus vaccination
Wed, 26 Aug 2015 22:27:39 +0100 | Autonomic Neuroscience: Basic and Clinical
Previous results and discussions reported from various countries for possible adverse symptoms after human papilloma virus vaccination (HPVV) have been controversial. The aim of this study was to clarify the characteristic manifestations of these symptoms common for these patients. We have had opportunities for investigating over 100 Japanese patients with various symptoms after HPVV. Complete neurological examinations were done for 10 selected patients hospitalized in a neurology ward. All were females, 14-20 aged (median 17.0 aged). (Source: Autonomic Neuroscience: Basic and Clinical)